Mammographic screening and risk factors for breast cancer.

Screening mammography can distort estimated effects in breast cancer risk models due to associations with other risk factors. Mammography information was available in the Nurses' Health Study from 1988, and 1,815 incident breast cancers were accrued through 2000 among 55,625 women with risk factor data. Logistic models were fit for screening mammography, and inverse probability weighting was used to adjust parameters in an established breast cancer risk model. Approximately 80% of women in each 2-year follow-up period had screening mammograms, which were positively associated with history of benign breast disease, family history of breast cancer, hormone therapy, alcohol use, physical activity, multivitamins, and calcium supplements, and negatively associated with postmenopause, current smoking, and body mass index. Markers of medical attention, including hypertension, high cholesterol, and osteoarthritis, were positively associated, while cardiovascular disease was negative. Inverse probability weighting led to small changes in effects of benign breast disease, family history, and hormone therapy. An apparent reduced risk associated with current smoking in unadjusted models was eliminated after weighting. Thus, several risk factors for breast cancer and cancer diagnosis are associated with mammographic screening. Adjustment for screening had some impact on breast cancer prediction in this cohort, especially for hormone therapy and smoking.

[1]  M. Pike,et al.  Ethnic differences in the use of regular mammography: the multiethnic cohort , 2009, Breast Cancer Research and Treatment.

[2]  Lewis H Kuller,et al.  Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. , 2008, American journal of epidemiology.

[3]  J. Palmgren,et al.  On informative detection bias in screening studies , 2008, Statistics in medicine.

[4]  S. Weitzen,et al.  "Weighing in" on screening mammography , 2008 .

[5]  Lewis H Kuller,et al.  Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. , 2008, American journal of epidemiology.

[6]  J. Manson,et al.  Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. , 2008, JAMA.

[7]  Karla Kerlikowske,et al.  Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.

[8]  D. Miglioretti,et al.  Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. , 2007, Journal of the National Cancer Institute.

[9]  Karla Kerlikowske,et al.  Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.

[10]  J. Robins,et al.  Estimating causal effects from epidemiological data , 2006, Journal of Epidemiology and Community Health.

[11]  D. Berry,et al.  Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .

[12]  Albert W Wu,et al.  The influence of health status, age, and race on screening mammography in elderly women. , 2005, Archives of internal medicine.

[13]  J. Hux,et al.  Reduced screening mammography among women with diabetes. , 2005, Archives of internal medicine.

[14]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[15]  Roger B. Davis,et al.  Obesity and breast cancer screening , 2004, Journal of General Internal Medicine.

[16]  Graham A Colditz,et al.  Risk factors for breast cancer according to estrogen and progesterone receptor status. , 2004, Journal of the National Cancer Institute.

[17]  M. Joffe Invited commentary: screening as a nuisance variable in cancer epidemiology: methodological considerations. , 2003, American journal of epidemiology.

[18]  N. Weiss Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. , 2003, American journal of epidemiology.

[19]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[20]  S. Cole,et al.  Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. , 2002, American journal of epidemiology.

[21]  G. Colditz,et al.  Postmenopausal Hormone Use, Screening, and Breast Cancer: Characterization and Control of a Bias , 2001, Epidemiology.

[22]  D. Allison,et al.  Body weight and cancer screening among women. , 2001, Journal of women's health & gender-based medicine.

[23]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[24]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[25]  Daniel S. Miller,et al.  Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)--Behavioral Risk Factor Surveillance System. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[26]  J Schwartz,et al.  Air pollution and hospital admissions for heart disease in eight U.S. counties. , 1998, Epidemiology.

[27]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[28]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[29]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States) , 1994, Cancer Causes & Control.

[30]  J. Robins,et al.  Identifiability and Exchangeability for Direct and Indirect Effects , 1992, Epidemiology.

[31]  S. Thacker,et al.  A Meta-analysis of the Effect of Estrogen Replacement Therapy on the Risk of Breast Cancer , 1991 .

[32]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[33]  Use of mammograms among women aged > or = 40 years--United States, 2000-2005. , 2007, MMWR. Morbidity and mortality weekly report.

[34]  J. Pearl,et al.  Causal diagrams for epidemiologic research. , 1999, Epidemiology.

[35]  G. Shaw,et al.  Maternal pesticide exposure from multiple sources and selected congenital anomalies. , 1999 .

[36]  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. , 1997, Lancet.